Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
UBS
AstraZeneca
Cantor Fitzgerald
McKesson
Farmers Insurance
Queensland Health
Fish and Richardson
Fuji
Harvard Business School

Generated: January 16, 2018

DrugPatentWatch Database Preview

EVISTA Drug Profile

« Back to Dashboard

Which patents cover Evista, and what generic alternatives are available?

Evista is a drug marketed by Lilly and is included in one NDA. There are four patents protecting this drug.

This drug has forty-five patent family members in thirty-three countries and two supplementary protection certificates in two countries.

The generic ingredient in EVISTA is raloxifene hydrochloride. There are sixteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the raloxifene hydrochloride profile page.
Drug patent expirations by year for EVISTA
Pharmacology for EVISTA

US Patents and Regulatory Information for EVISTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for EVISTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Premature patent expiration for: EVISTA

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
➤ Subscribe EVISTA ➤ Subscribe
➤ Subscribe EVISTA ➤ Subscribe

International Patents for EVISTA

Supplementary Protection Certificates for EVISTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/048 United Kingdom ➤ Subscribe PRODUCT NAME: RALOXIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/98/073/001 19980805; UK EU/1/98/073/002 19980805; UK EU/1/98/073/003 19980805; UK EU/1/98/073/004 19980805; UK EU/1/98/074/001 19980805; UK EU/1/98/074/002 19980805; UK EU/1/98/074/003 19980805; UK EU/1/98/074/004 19980805
0044 Netherlands ➤ Subscribe PRODUCT NAME: RALOXIFENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/98/073/001 - EU/1/98/073/004, EU/1/98/074/001 - EU/1/98/074/004 19980805 EU/1/98/073/001
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Teva
Johnson and Johnson
AstraZeneca
Covington
Deloitte
US Department of Justice
Healthtrust
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot